Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

T Escoda1, A Benyamine1, P Belenotti2

  • 1Service de médecine interne, Hôpital Nord, Pôle MICA, Assistance Publique Hôpitaux de Marseille (AP-HM), Aix-Marseille Université, Marseille, France.

La Revue De Medecine Interne
|September 2, 2020
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Burden of incident cardiovascular events in giant cell arteritis using data from a nationwide French cohort.

Scientific reports·2026
Same author

[A reticular aspect of the abdomen].

La Revue de medecine interne·2026
Same author

[Fever in a 74-year-old man].

La Revue de medecine interne·2025
Same author

Search for Light Dark Matter in Low-Energy Ionization Signals from XENONnT.

Physical review letters·2025
Same author

First Search for Light Dark Matter in the Neutrino Fog with XENONnT.

Physical review letters·2025
Same author

First Indication of Solar ^{8}B Neutrinos via Coherent Elastic Neutrino-Nucleus Scattering with XENONnT.

Physical review letters·2024
Same journal

[Abdominal pain, fever and arthralgia in a 49-year-old woman].

La Revue de medecine interne·2026
Same journal

[Cardiorespiratory functional disorders: A transnosologic approach].

La Revue de medecine interne·2026
Same journal

[Diagnostic evaluation for suspected polycythemia].

La Revue de medecine interne·2026
Same journal

Heart involvements in systemic sclerosis beyond pulmonary hypertension: From conduction, rhythm and function defects to coronary artery disease.

La Revue de medecine interne·2026
Same journal

[Acute intermittent porphyria: When diagnostic errance jeopardizes patient health].

La Revue de medecine interne·2026
Same journal

Autosomal dominant polycystic kidney disease: Current perspectives in 2026.

La Revue de medecine interne·2026
See all related articles
This summary is machine-generated.

Axial skeleton involvement in sarcoidosis, though previously rare, is increasingly recognized. This condition can cause significant bone pain and disability but responds well to standard sarcoidosis treatments.

Area of Science:

  • Rheumatology
  • Orthopedics
  • Radiology

Background:

  • Sarcoidosis is a systemic inflammatory disease characterized by granuloma formation.
  • Bone involvement in sarcoidosis, once thought rare and peripheral, now includes axial skeleton sites.
  • Recent findings highlight sarcoidosis affecting the spine, pelvis, and other axial bones.

Observation:

  • Four cases of sarcoidosis with axial bone involvement (spine, pelvis, scapula, sternum, mandible) are presented.
  • Bone pain was the primary symptom in most patients.
  • Magnetic resonance imaging (MRI) proved effective for diagnosis, with histological analysis confirming granulomas.

Findings:

  • Axial bone sarcoidosis is symptomatic in approximately 50% of cases, potentially leading to disability.
Keywords:
Bone lesionGranulomaGranulomeLésions osseusesRachisSarcoidosisSarcoïdoseSpine

Related Experiment Videos

  • Histological examination is crucial for differentiating sarcoidosis bone lesions from neoplasms.
  • Standard sarcoidosis therapies, including corticosteroids, hydroxychloroquine, and methotrexate, effectively manage bone pain.

    • Implications:

    • Increased awareness of axial skeletal sarcoidosis is necessary for timely diagnosis and management.
    • Early detection and treatment can mitigate significant disability associated with bone sarcoidosis.
    • This study reinforces the efficacy of established sarcoidosis treatments for managing bone manifestations.